secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucira Health, Inc. (—)
CIK:        0001652724
Form:       8-K
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0001193125-23-044968
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 1.03, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lucira Health files Chapter 11 bankruptcy, plans sale of business
-----------------------------------------------------------------

- Filed Chapter 11 in Delaware on Feb 22, 2023; intends to sell business under Section 363 of Bankruptcy Code.
- Cash on hand ~$4.5M; no debtor-in-possession financing required; funds operations and sale process.
- Four directors resigned (Tuff Yen, Alison McCauley, Sandra Gardiner, Steve Tablak) effective Feb 17; Michael Wyse appointed lead independent director at $25k/month.
- Bankruptcy driven by lower COVID-19 test demand and delayed FDA EUA for COVID-19/Flu combo test.
- Company cautions common stock holders may receive no distribution; trading highly speculative.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652724/000119312523044968/0001193125-23-044968-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652724/000119312523044968/d642141d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-044968

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer